Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (161)
  2. Journal Article (107)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Solid Tumor Oncology Division (288)
  3. Thoracic Oncology (288)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (103)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (17)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (74)
  2. Journal of Thoracic Oncology (62)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (84)
  2. American Society of Clinical Oncology (83)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (288)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US
    Meeting Abstract

    Sabari, J. K.; Yu, H. A.; Mahadevia, P.; Liu, Y.; Demirdjian, L.; Sultan, A. A.; Chen, Y. H.; Wang, X.; Passaro, A.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Proton craniospinal irradiation for patients with solid tumor leptomeningeal metastasis- Final analysis of a phase II study
    Meeting Abstract

    Yang, J. T.; Yerramilli, D.; Pentsova, E.; Wolden, S. L.; Young, R. J.; Correa, D.; Zhang, Z.; Zheng, J.; Baser, R. E.; Betof Warner, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Automated real-world data integration improves cancer outcome prediction
    Journal Article

    Jee, J.; Fong, C.; Pichotta, K.; Tran, T. N.; Luthra, A.; Waters, M.; Fu, C.; Altoe, M.; Liu, S. Y.; Maron, S. B.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
    Journal Article

    Hickman, R. A.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gewirtz, A. N.; more...
    Acta Neuropathologica Communications (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in previously untreated, advanced nonsquamous NSCLC patients with EGFR exon 20 insertions
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced NSCLC with exon 20 insertions and other uncommon EGFR mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Jayakrishnan, R.; Nassar, A.; Shepherd, F. A.; Lin, J. J.; Lin, S. H.; Shakya, P.; Dilling, T. J.; Bar, J.; Grohe, C.; Gupta, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, L.; Wei, Y.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save